Alnylam Presents New Clinical, Real-World Data From Cardiovascular Portfolio At ACC.26, Reinforcing Potential Of RNAi To Deliver Fundamentally Differentiated, Effective, And Durable Impact For Patients Living With CVD

Alnylam Pharmaceuticals presented new clinical and real-world data from its cardiovascular portfolio at ACC.26, highlighting the effectiveness of vutrisiran in improving health-related quality of life for patients with ATTR-CM. The data showed that vutrisiran provides meaningful benefits across the disease spectrum, including advanced cases. Additionally, pooled Phase 2 safety data for zilebesiran indicated a favorable safety profile for this investigational treatment for hypertension, supporting its further evaluation in a Phase 3 trial set to begin in September 2025.